

上海復星醫藥（集團）股份有限公司  
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

## 2014 FIRST QUARTERLY REPORT

(1

$$).$$

201 ( ) ., “Group”).

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***  
**Chen Qiyu**  
*Chairman*

201

[illegible]

\*  $F_{\text{max}}$  is the maximum force exerted by the muscle.

## 1 IMPORTANT NOTICE

## 1.1

1.2

1.  $\frac{1}{2} \leq \frac{1}{2} \leq \frac{1}{2}$ ,  $\frac{1}{2} \leq \frac{1}{2} \leq \frac{1}{2}$  (, , )

1.

## 2 MAJOR FINANCIAL INFORMATION OF THE GROUP AND CHANGES IN SHAREHOLDINGS OF THE COMPANY

## 2.1

[illegible]

Items	Current Amount (Jan – Mar)	Description
-	0, , 0.	
,	1,000.00	
, - - ,	11 , 0, 1 .21	- -
-	-1, ,0 2.	
	- , , 01.	
( )	- , 02,0 1.	
	110, , .	

2.2

,

10

10

:

				,2 0	
The shareholding status of the Top 10 shareholders					
Name of the shareholder	Capacity	Shareholding (%)	Total number of shares held	Number of restricted shares held	Number of shares pledged or frozen
( ) , .	- -	1.02	20, 1, 1	0	
		1 .	, 1 , 0	0	
10		1.22	2 , , 2	0	
—		0.	1 ,2 1,	0	
— -		0. 0	1 ,000,000	0	
11		0.	1 , ,22	0	
-		0.	1 , 02, 0	0	
—		0.	12, , 1	0	
—		0. 1	11, ,	0	
— — 01 —		0.	10,1 2, 0	0	
002					

The shareholding status of the Top 10 unrestricted shareholders of tradable shares		
Name of the shareholder (in full)	Number of unrestricted tradable shares held at the end of the reporting period	Type and number of shares
( ) , .	20, 1, 1	
(N <sub>4</sub> )	, 1 , 0	
10	2 , , 2	
—	1 ,2 1,	
— -	1 ,000,000	
11	1 , ,22	
-	1 , 02, 0	
—	12, , 1	
—	11, ,	
— 01 — 002 — —	10,1 2, 0	
	<div>—</div> <div>—</div> <div>., .</div> <div>—</div> <div>-</div> <div>.</div> <div>.</div>	

N<sub>4</sub> :
, . . ,

3 SIGNIFICANT EVENTS

.1

✓ ☐

Balance Sheet				
Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year	Ratio of change	Reasons
-	2,0 , ,121.20	1, , 00, 2 .	%	-
-	2 , 2 , 1. 2	12 , 1 ,1 1. 2	1 1%	-

Income Statement				
Items	Current Amount	Amount of the last period	Ratio of change	Reasons
	(Jan – Mar 2014)	(Jan – Mar 2013)		
	1, ,0 , .	1,1 2, , 0 .	%	
	1, 2 ,2 . 2	2 ,0 ,110.1	%	&
(“-” )	1, ,0 1.	2, 1, 2.	– %	
(“-” )	01, 1 , . 2	2 ,200,01 .1	%	,
-	, , 0 .0	1 ,0 0, .	– %	
	2,11 , .	0, 0 , . 0	%	,
	– ,10 , 2.	2 , , .	– 2%	



( ) 2 201 , ( )

，

\* (上

## 4 APPENDICES

## Consolidated Balance Sheet

31 May • 2014

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***[illegible]



### Consolidated Balance Sheet (Continued)

31 May • 2014

[illegible]

## 31 Mei • 2014

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
<b>Current Assets:</b>		
	1 ,01 , 0 . 0	2 ,1 1, . 1
	,121, 0 .	2 , , . 0
	1 , ,22 .	1 , ,22 .
	1, 0,02 , .1	1, , ,21 .0
	1 , .	1 , .
-		
	,000,000.00	2 ,000,000.00
	, , 0, 2 . 1	,0 2,01 ,22 .
<b>Non-current assets:</b>		
- -		
- -		
-		
-	, 2 , , . 0	, 0, , 2.
	1 , , 2 .1	20,1 ,0 .
	2, 0 , 11.	,0 ,0 . 2
-		
-	, 1, , .1	,0 2, ,2 2. 0
-	, , , 0 .	, , 1 , .
	1 ,1 ,2 ,0 .	12, , ,21 . 0

## Balance Sheet of the Company (Continued)

31 Mē . • 2014

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
<b>Current liabilities:</b>		
-	10,000,000.00	0,000,000.00
	, 0, .	0, 2 , 11.
	1 ,1 ,0 .02	22,22 , .
	10 ,2 2, 0.	1 , , 1 .
	,1 , .	, 12, 2 .
-	0,000,000.00	0,000,000.00
	1,0 , 1 ,1 . 2	2 ,02 ,0 1.0
<b>Non-current liabilities:</b>		
-	2 ,000,000.00	12 ,000,000.00
	,0 , 2 , 1.	,0 , 1,2 0.
-		
-	1, ,000.00	2,0 0,000.00
-	, 02, 02, 1.	,200, 1,2 0.
	, , 1 , .	, 2 , ,2 1.
<b>Equity attributable to the owners (or equity attributable to shareholders):</b>		
- ( )	2,2 , , .00	2,2 0, 2, .00
	, ,20 ,2 .	, , 1,2 . 1
	, 0,1 .	, 0,1 .
	1,0 , 22, 11.	1,0 , 1,0 1. 2
( )	, , 1 , 1.0	, 1, , .0
( )	1 ,1 ,2 ,0 .	12, , 2,1 . 0

# Consolidated Income Statement

2014

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Items	Current Amount	Amount of the Last Period
.	2, , 2, .	2,0 , , 1.2
	2, , 2, .	2,0 , , 1.2
.	2, 20, , 0 . 1	1, 2 , , 1 .
	1, ,0 , .	1,1 2, , 0 .
	1 , , 2.2	1 , 02, 2.1
	02, 1,211.12	0 , 02, .
	1, 2 ,2 . 2	2 ,0 ,110.1
	2, 1, .	, ,210.
	1,220, 12. 0	1 , 2. 2
(“ ” )	1, ,0 1.	2, 1, 2.
(“ ” )	01, 1 , . 2	2 ,200,01 .1
	2 , 0, 2.1	1 , , . 1
(“ ” )		
(“ ” )	0, ,0 2.	, 01,1 .
-	, , 0 .0	1 ,0 0, .
-	, 12, .0	2 ,0 .
-	, 1.	, 0.0
(“ ” )	,000,2 .	2, 0 , 2 .
	2,11 , .	0, 0 , . 0
(“ ” )	2, 0, .	12, , .
	1 , 1 , . 12	2,00 ,2 . 1
/	, 0, . 1	0, 0, 1.
.		
(1)	0.1	0.1
(2)	0.1	0.1
.	- ,10 , 2.	2 , , .
.	1 , 0, 2.	, , 1.20
	1, 1 ,1 .	0, ,0 .2
	,2 , . 2	,0 , 0 .

# Income Statement of the Company

2014

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Items	Current Amount	Amount of the Last Period
.		
	2, 10, 1 .	20, 2 ,00 .02
	- ,1 ,20 . 1	,20 , . 2
(“-” )		
(“-” )	2 ,10 ,22 .	2 , 1, .
	2 , 0 , 2 .	, ,2 2.
(“-” )	-1,02 , .	2 , 0, .
-	,000.00	,0 2.
-	2 0,000.00	,11 . 2
-		
(“-” )	-1,20 , .	2 , ,2 .02
(“-” )	-1,20 , .	2 , ,2 .02
.		
(1)	-0.00	0.12
(2)	-0.00	0.12
.		,2 . 0
.	-1,20 , .	2 , 0 , 1 . 2

## Consolidated Statements of Cash Flows

*J. Bus. Ethics* (2014)

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

Items	Current Amount	Amount of the Last Period
<b>I. Cash flow generated from operating activities:</b>		
	,0 , 22, .	2, , ,0 .
-		
	1 , 0 , . 0	,2 , .
	0, , 2 .	, , 0.
-	,12 , , .1	2, , , .
	1, 11, 1 , .	1, 0 , ,2 2.
-		
	, 20,2 . 0	1 , , 22.
	2 , , 01.	2 , 2 ,22 .
	, , 1 .	, , 1. 0
-	,11 , , .	2, 01, 1 , .2
	,02 , 1 .	,1 , 1.
<b>II. Cash flow generated from investing activities:</b>		
	1 , 1,10 .	1 , , 0.10
	0, 0 .	,1 , .00
	, 1, .	2,0 , 22.22
	, 1 , .	
	0,10 ,000.00	, 0,000.00
-	2 , ,1 1.	1 , 2 , . 2
	, , .	22 , 1,2 .21
	, , 2.	1,2 0,000.00
	1 , 10, . 0	1, 1 , 2.
	1,2 1,1 .2	1 , , .
-	, 1 , . 1	2 , , 21.
	- , 1 , 2 .	- , ,0 .

## Consolidated Statements of Cash Flows (Continued)

*For the period ended March 31, 2014*

Items	Current Amount	Amount of the Last Period
<b>III. Cash flow generated from financing activities:</b>		
	,1 0.00	
	,1 0.00	
	1, 2 , 1.	1 ,0 , 02.00
	21 , .	
-	2,20 , 20.	1 ,0 , 02.00
	12 ,2 ,2 .	1 , 0, 1 .
,	20 ,22 , .	1 ,2 , 00.
	0,000,000.00	1, 2, 0 .
	1, , 1.	,2 ,0 . 2
-	0, , 0 .10	2, ,2 .
	1, , 1 .	-1 , 0 , .
<b>IV. Effects of exchange rate fluctuations on cash and cash equivalents</b>	, , .00	- , 0 , .
<b>V. Net increase of cash and cash equivalents</b>	,000,201.	- , 2,1 .2
	2, 1 ,2 0, .2	,1 1, , 2.12
<b>VI. Closing balance of cash and cash equivalents</b>	2, ,2 0, 1.0	, 1 , 2, 0 .

*J. Bus. Ethics* (2014)

[illegible]



## Statements of Cash Flows of the Company (Continued)

December – March 2014

Items	Current Amount	Amount of the Last Period
<b>III. Cash flow generated from financing activities:</b>		
	0,000,000.00	
	1, , , . 1	, , 1. 0
-	2, 2 , , . 1	, , 1. 0
	10 ,1 , .	10 , 00,000.00
	1, ,2 , .	02, ,0 . 2
-	1, , 2, 1.	0 ,1 ,0 . 2
	, 1, 1.	-2 ,211, 0 .22
<b>IV. Effects of exchange rate fluctuations on cash and cash equivalents</b>	,12 , . 1	- , 2, . 1
<b>V. Net increase of cash and cash equivalents</b>	-1 ,11 , 2.11	- 2,1 , 2.
	1 ,2 2, . 1	2,0 0, 1,0 .
<b>VI. Closing balance of cash and cash equivalents</b>	0 ,1 , 0 . 0	1, , 1, 0.

\* Financial statements are prepared in accordance with the accounting standards of the Republic of Armenia.